65,437 trials
Contraception · Menorrhagia
Primary: Number of Pregnancies at 1-year Time Point (1-year Pregnancy Rate) — 0 Pregnancy
Smoking · Schizophrenia
Primary: Change in Acetylcholine (ACh) Levels After Physostigmine Administration as Confirmed by PET Images. — 5.9; 4.3 percentage of change
HIV Infections
Primary: Number of Participants With Grade 2 or Higher Adverse Events (AEs) — 36; 36; 88; 87 Participants — p=0.92
Alcohol Use Disorders · Stress Disorders, Posttraumatic · Combat Disorders
Primary: Change in Penn Alcohol Craving Scale Score — 7.4; 8.8 units on a scale
Alcohol Use Disorder
Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065
Anesthesia, Local · Pain
Primary: VAS — 2.5; 2.3; 2.7; 4.2 score on a scale — p=0.001
Chemotherapy-induced Neutropenia
Primary: Duration of Severe Neutropenia in Cycle 1 — 0.9; 1.6; 1.1; 0.9 days
HIV · Contraception
Primary: AGYW Patronage (Count) — 1.0; 1.0; 1.7; 1.0 AGYW customers per observation
Malaria
Primary: Pyronaridine Pharmacokinetics: Tmax, Half-life — 0.184; 0.166; 14.2; 14.1 days
Cardiovascular Risk Factor · Stress · Self Efficacy
Primary: American Heart Association's Life's Simple Seven (LS7) Score — 8.76; 8.21 units on a scale
Chronic Ischemic Stroke
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 1; 1; 0; 3 Participants
Cancer
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 2; 183; 4; 317 Participants
Cardiorespiratory Failure
Primary: Change in Hospital Anxiety and Depression Scale (HADS) Questionnaire — 11.7; 11.3; 12.1 units on a scale
Graft vs Host Disease
Primary: Overall Response Rate (ORR) — 84.2 Percentage of participants
Pregnancy in Adolescence · Counseling · Contraception Behavior
Primary: Intention to Initiate Contraception — 59 Participants